AdAlta Limited news

AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform, is pleased to advise that CEO and Managing Director, Dr Tim Oldham, has been selected to present at the Bio International Convention in San Diego, California on Monday 13 June, US time.

BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizatio

AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform, is pleased to advise that CEO and Managing Director, Dr Tim Oldham, will be presenting at the 16th Bioshares Biotech Summit in Albury, NSW on 11 May 2022.

The Bioshares Biotech Summit’s unique format brings together biotechnology companies and equity capital markets participants to explore not just what biotechnology companies do but just as importan

AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform, is pleased to announce that its first Indian patent relating to lead program, AD-214, has been granted by the Indian Patent Office.

Patent Number 398125, entitled "CXCR4 binding molecules", has an expiry date of 8 January 2036.

The new patent protects the i-body sequence used in AdAlta`s lead product, AD-214, sequences similar to this, and pharmace